CFTR and COVID-19: The drug of the second generation of CFTR modulators—elexacaftor/tezacaftor/ivacaftor (VX-445 + VX-661 + VX-770)—prescribed after an additional examination on intestinal organoids, showed a clinical effect of 16%, despite COVID-19, lung damage, and the presence of chronic aspergillosis.